Results 111 to 120 of about 517,111 (322)

Key inflammatory pathway activations in the MCI stage of Alzheimer's disease [PDF]

, 2019
OBJECTIVE: To determine the key inflammatory pathways that are activated in the peripheral and CNS compartments at the mild cognitive impairment (MCI) stage of Alzheimer's disease (AD).
Bekris, Lynn M., Bena, James, Chance, Mark, Lamb, Bruce T., Leverenz, James B., Maxwell, Sean, Pillai, Jagan A., Rao, Stephen M.   +7 more
core   +2 more sources

Fluid and Neuroimaging Biomarkers in Microgliopathy Colony‐Stimulating Factor‐1 Receptor‐Related Disorders

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective This study aims to identify both fluid and neuroimaging biomarkers for CSF1R‐RD that can inform the optimal timing of treatment administration to maximize therapeutic benefit, while also providing sensitive quantitative measurements to monitor disease progression.
Tomasz Chmiela, Madison Reeves, Karen Jansen‐West, Judith Dunmore, Yuping Song, Audrey Strongosky, Sunil Gandhi, Gilana Pikover, Matt Blurton‐Jones, Robert C. Spitale, Erik H. Middlebrooks, Leonard Petrucelli, Mercedes Prudencio, Zbigniew K. Wszolek   +13 more
wiley   +1 more source

Survival of Interleukin-17 and Interleukin-23 Inhibitors in Patients Previously Treated With a Tumor Necrosis Factor Inhibitor: Analysis of the Spanish Biobadaderm Registry

Actas Dermo-Sifiliográficas
Interleukin 12/23 inhibitors (IL12/23i) and interleukin 17 and 23 inhibitors (IL17i and IL23i) represent the drug classes with the most favorable expectations for therapeutic response.
R. Rivera-Díaz, A. Quesada, A. Sahuquillo-Torralba, E. Daudén, J.M. Carrascosa, I. Belinchón, F.J. Gomez Garcia, E. Herrera Acosta, D.P. Ruiz Genao, O. Baniandrés Rodriguez, M. Ferrán Farres, P. de la Cueva Dobao, L.R. Fernández-Freire, A. Mateu Puchades, J. Riera-Monroig, J.C. Ruiz Carrascosa, M. Ara Martín, M. Abalde Pintos, M. Roncero Riesco, J.L. Lopez-Estebaranz, C. García-Donoso, I. García-Doval, M. Angel Descalzo   +22 more
doaj   +1 more source

P024 Effects of anti-TNF and anti-interleukins 12 and 23 drugs on circulating dendritic cells migratory capacity in inflammatory bowel disease [PDF]

, 2023
Irene Soleto, Cristina Ramírez, Carmen Navarro Gómez, B Montse, Sergio García García, Macarena Orejudo, J Mecado, María Chaparro, Javier P. Gisbert   +8 more
openalex   +1 more source

Olink Proteomics Analysis Reveals Heterogeneous Responses to FcRn Blockade in Anti‐AChR Antibody‐Positive Myasthenia Gravis: FGF‐19 as a Novel Biomarker

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective This study aimed to systematically observe the clinical manifestations, immune cell subsets, and dynamic changes in serological indicators in patients with myasthenia gravis (MG) before and after efgartigimod (EFG) treatment. Methods We analyzed the baseline data, laboratory parameters, and lymphocyte subset proportions in MG ...
Tiancheng Luo, Deyou Peng, Zhouao Zhang, Mingjin Yang, Xinyan Guo, Tianyu Ma, Xiaoyu Huang, Mingming Xu, Linlin Fu, Yong Zhang   +9 more
wiley   +1 more source

Ustekinumab in treatment of Crohn’s disease: design, development, and potential place in therapy

Drug Design, Development and Therapy, 2016
Parakkal Deepak, Edward V Loftus Jr Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN, USA Abstract: Crohn’s disease is characterized by a dysregulation of both innate and adaptive immunity responses ...
Deepak P, Loftus EV Jr
doaj  

Interleukin‐12/23 and Interleukin‐23 Inhibitors for the Treatment of Cutaneous Crohn's Disease: A Case Series From a Multi‐Institutional Registry

JEADV Clinical Practice
Background Cutaneous Crohn's disease (CCD) is a granulomatous condition of the skin discontiguous from the gastrointestinal tract. Cutaneous disease rarely correlates with intestinal disease and often requires separate treatment.
G. E. McKay, A. Coromilas, L. Liu, K. S. Shaw, M. Murphy, N. Punyamurthy, K. M. Santiago Soltero, W. Damsky, K. A. Wanat, A. P. Charrow, M. Rosenbach, A. Caplan, C. E. LaSenna, L. Arkin, B. E. Shields   +14 more
doaj   +1 more source

The role of the novel Th17 cytokine IL-26 in intestinal inflammation [PDF]

, 2008
Background and aims: Interleukin 26 (IL-26), a novel IL-10-like cytokine without a murine homologue, is expressed in T helper 1 (Th1) and Th17 cells. Currently, its function in human disease is completely unknown. The aim of this study was to analyse its
Auernhammer, Christoph J., Beigel, Florian, Brand, Stephan, Dambacher, J., Diepolder, Helmut M., Göke, Burkhard, Toni, Enrico N. de, Zitzmann, K.   +7 more
core   +1 more source

Evaluation of the Efficacy and Safety of Satralizumab in a Pregnant NMOSD Patient With AQP4/MOG‐IgG Dual Seropositive: A Case Report

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Neuromyelitis Optica Spectrum Disorder (NMOSD) is a chronic autoimmune neuroinflammatory disease, typically characterized by antibodies against aquaporin 4 (AQP4‐IgG) or myelin oligodendrocyte glycoprotein (MOG‐IgG). Simultaneous seropositivity for both antibodies in a single patient is exceedingly rare.
Yeting Luo, Shuhua Xie, Xianghong Liu
wiley   +1 more source

Immune‐Driven Expression in Inclusion Body Myositis With T‐Cell Large Granular Lymphocytic Leukemia

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objectives T‐cell large granular lymphocytic leukemia (T‐LGLL), reported in up to 58% of inclusion body myositis (IBM) patients, is a rare leukemia of cytotoxic or less commonly helper T cells. The range of myopathies in T‐LGLL and the impact of coexisting T‐LGLL in IBM are not well understood. Our objectives are to investigate the spectrum of
Pannathat Soontrapa, Iago Pinal‐Fernandez, Pritikanta Paul, Michael P. Skolka, Margherita Milone, Min Shi, Mithun V. Shah, Maria Casal‐Dominguez, Katherine Pak, Andrew L. Mammen, Teerin Liewluck   +10 more
wiley   +1 more source